A French pharmaceutical company that licensed the selling, marketing and regulatory approval of its product in the United States to an American distributor cannot pursue antitrust claims against Abbott Laboratories because it foreclosed upon competing in the U.S. market by not directly offering the drug or seeking regulatory approval itself, the U.S. Court of Appeals for the Third Circuit has ruled in a precedential opinion.
Antitrust Claims Against Abbott Labs Tossed
Delaware Law Weekly
February 6, 2013
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.